Navigation Links
Medical societies to launch large-scale study on vein filter use

FAIRFAX, Va.The Society of Interventional Radiology and Society for Vascular Surgery jointly will launch PRESERVEthe first large-scale, multispecialty prospective study to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment.

The studyalong with the formation of the IVC Filter Study Group Foundationare direct actions taken to address the August 2010 FDA medical alert detailing the possibility that retrievable IVC filters could move or break, potentially causing significant health risks for patients. SIR and SVS are in the process of determining a framework for the PRESERVE (PREdicting the Safety and Effectiveness of InferioR VEna Cava Filters) study, with the goal of obtaining a functional view of all filters placed in the United States.

"PRESERVE data will allow a systematic, functional view, representative of all filters placed in the United States, thus, all stakeholdersindividuals, health care professionals, insurers and government regulatorswill be armed with the knowledge they need on patient risk and, subsequently, quality improvement in filter placement, management and retrieval," said SIR President Marshall E. Hicks, M.D., FSIR.

"This is a paradigm-shifting initiative: interventional radiologists and vascular surgeons collaborating to launch a large-scale prospective study evaluating inferior vena cava filters reveals a lot about each specialty's focusand that focus is on patients, first and foremost," noted SVS President Peter Gloviczki, M.D.

The five-year study will evaluate the overall safety and efficacy of filters placed by doctors and intends to enroll 1,800 patients at approximately 50 centers in the United States. Members of the IVC Filter Study Group Foundation collectively discussed ways to respond to the FDA's stated concerns. SIR and SVS are in the process of making a final decision for a contract research organization, completing protocol development and submitting the study for investigational device exemption (IDE) study with HIPAA (Health Insurance Portability and Accountability Act) compliance. Study directors are Matthew S. Johnson, M.D., FSIR, Indiana University School of Medicine, Indianapolis, Ind., and David L. Gillespie M.D., FACS, University of Rochester School of Medicine and Dentistry, Rochester, N.Y. Most filter manufacturers have agreed to participate in the study.

According to the U.S. Surgeon General, between 350,000 and 600,000 people each year in the United States are affected by blood clots and between 100,000 and 180,000 people die of pulmonary embolism (a blood clot that travels to the lungs) each year. IVC filters are placed inside patients by vascular specialists to prevent blood clots from breaking free and traveling to the lungs or heart and causing a pulmonary embolism. FDA recommendations are that physicians remove the filters, which are designed to be retrievable, once the threat of pulmonary embolism has passed. The FDA warning said that all physicians were encouraged to consider the benefits and health risks of IVC filter removal for each patient.

Members of the IVC Filter Study Group Foundation board of directors are SVS President Peter Gloviczki, M.D., Mayo Clinic College of Medicine, Rochester, Minn. (president); SIR President Marshall E. Hicks, M.D., FSIR, University of Texas MD Anderson Cancer Center, Houston (vice president); SVS Executive Director Rebecca M. Maron, CAE (secretary); SIR Executive Director Susan E. Sedory Holzer, MA, CAE (treasurer); John A. Kaufman, M.D., MS, FSIR, Dotter Interventional Institute, Portland, Ore. (SIR representative); and Peter Lawrence, M.D., UCLA Medical Center, Santa Monica (SVS representative).


Contact: Ellen Acconcia
Society of Interventional Radiology

Related biology news :

1. Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings
2. Miniature pressure sensors for medical touch
3. Research!America says house funding levels for FY13 could undermine medical progress
4. Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship
5. Medical device, health professionals attend first national conference on value-driven engineering
6. Ultrasensitive biosensor promising for medical diagnostics
7. UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure
8. Tufts Medical Center researchers finds marker in premies saliva predicts readiness to feed by mouth
9. CDS Monarch Deploys DigitalPersona Strong Authentication Solutions for Secure Access to Electronic Medical Records
10. Nuisance seaweed found to produce compounds with biomedical potential
11. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
Post Your Comments:
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
Breaking Biology Technology: